{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:53:21Z","timestamp":1791395601804,"version":"4.3.3"},"reference-count":25,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:00:00Z","timestamp":1548201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:p>Objective: To review the pharmacology, pharmacokinetics, clinical trials, and clinical implications of baloxavir marboxil. Data Sources: A MEDLINE search was conducted using the terms baloxavir, baloxavir marboxil, cap-dependent endonuclease inhibitor, and polymerase acidic endonuclease inhibitor. Additional data were obtained from the prescribing information and relevant guidelines. Study Selection and Data Extraction: All clinical trials were included. Data Synthesis: Baloxavir marboxil exploits a new mechanism of action of inhibiting cap-dependent endonuclease. Baloxavir was shown to be superior compared with placebo and noninferior compared with oseltamivir with regard to the primary end point. Baloxavir was well tolerated in the trials. A second phase III study investigating high-risk patients was completed with positive results. However, the full article is not yet published. Relevance to Patient Care and Clinical Practice: The small amount of literature limits baloxavir\u2019s use in certain patient populations. Baloxavir offers advantages such as single-dose regimen, eliminating adherence concerns and lack of cross-resistance, making it an alternative for resistant viruses. Several uncertainties remain. Baloxavir has not been studied in hospitalized patients, patients with symptoms for &gt;48 hours, or in combination with other antiviral agents. Furthermore, resistance to baloxavir can develop after 1 dose. Clinical studies are ongoing to evaluate baloxavir in young pediatric patients, hospitalized patients, and in combination therapy with neuraminidase inhibitors to further elucidate baloxavir\u2019s place in therapy. Conclusion: Baloxavir is a new antiviral medication for the treatment of influenza. Given the new mechanism of action, baloxavir may be useful in treating patients with resistant viruses.<\/jats:p>","DOI":"10.1177\/1060028019826565","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:48:03Z","timestamp":1548290883000},"page":"754-759","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":67,"title":["Baloxavir Marboxil: The First Cap-Dependent Endonuclease Inhibitor for the Treatment of Influenza"],"prefix":"10.1177","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5480-2541","authenticated-orcid":false,"given":"Tianrui","family":"Yang","sequence":"first","affiliation":[{"name":"University of Texas at Tyler Ben and Maytee Fisch College of Pharmacy, Tyler, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,1,23]]},"reference":[{"key":"bibr1-1060028019826565","unstructured":"Centers for Disease Control and Prevention. Disease burden of influenza. https:\/\/www.cdc.gov\/flu\/about\/burden\/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fflu%2Fabout%2Fdisease%2Fburden.htm. Accessed November 5, 2018."},{"key":"bibr2-1060028019826565","unstructured":"Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians. https:\/\/www.cdc.gov\/flu\/professionals\/antivirals\/summary-clinicians.htm. Accessed November 5, 2018."},{"key":"bibr3-1060028019826565","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis636"},{"key":"bibr4-1060028019826565","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq144"},{"key":"bibr5-1060028019826565","unstructured":"US Food & Drug administration. Drugs@FDA: FDA approved drug products. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&varApplNo=210854. Accessed November 5, 2018."},{"key":"bibr6-1060028019826565","unstructured":"Xofluza\u2122 [package insert]. South San Francisco, CA: Genen-tech USA, Inc; 2018."},{"key":"bibr7-1060028019826565","unstructured":"Rapivab\u2122 [package insert]. Durham, NC: BioCryst Pharmaceu-ticals, Inc; 2014."},{"key":"bibr8-1060028019826565","unstructured":"Xofluza\u2122 (baloxavir marboxil). Mechanism of action. https:\/\/www.xofluza.com\/hcp\/why-xofluza\/mechanism-of-action.html. Accessed December 13, 2018."},{"issue":"14","key":"bibr9-1060028019826565","first-page":"1","volume":"48","author":"Neuraminidase inhibitors for treatment of influenza A and B infections","year":"1999","journal-title":"MMWR Recomm Rep"},{"key":"bibr10-1060028019826565","doi-asserted-by":"publisher","DOI":"10.32607\/20758251-2009-1-2-26-32"},{"key":"bibr11-1060028019826565","doi-asserted-by":"publisher","DOI":"10.1038\/nature06531"},{"key":"bibr12-1060028019826565","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2018.10.008"},{"key":"bibr13-1060028019826565","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.12.2827"},{"key":"bibr14-1060028019826565","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0710-9"},{"key":"bibr15-1060028019826565","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716197"},{"key":"bibr16-1060028019826565","volume-title":"Paper presented at: ID Week 2018","author":"Ison MG"},{"key":"bibr17-1060028019826565","unstructured":"Peramivir [package insert]. Santa Monica, CA: GoodRx; 2018."},{"key":"bibr18-1060028019826565","unstructured":"Baloxavir marboxil [package insert]. Santa Monica, CA: GoodRx; 2018."},{"key":"bibr19-1060028019826565","unstructured":"Oseltamivir [package insert]. Santa Monica, CA: GoodRx; 2018."},{"key":"bibr20-1060028019826565","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-27890-4"},{"key":"bibr21-1060028019826565","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70267-6"},{"key":"bibr22-1060028019826565","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g2545"},{"key":"bibr23-1060028019826565","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky462"},{"key":"bibr24-1060028019826565","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0697-2"},{"key":"bibr25-1060028019826565","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000498"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028019826565","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028019826565","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028019826565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:50Z","timestamp":1777374890000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028019826565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,23]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1177\/1060028019826565"],"URL":"https:\/\/doi.org\/10.1177\/1060028019826565","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,23]]}}}